Recipient organisationNIHR Barts Biomedical Research Centre
NIHR supportRecorded as supported by this research centre
PeriodFeb 2025 — Jan 2028
In plain English
AI plain-English summary
Lung cancer patients in the UK will receive experimental drug combinations through a new clinical trial that tests whether these treatments work better than current standard therapies. This matters because lung cancer kills more people worldwide than any other cancer—roughly 1.8 million deaths in 2020 alone. For patients with metastatic non-small cell lung cancer, treatment options remain limited, and many tumours eventually stop responding to existing drugs. The trial is designed as a platform study, meaning it can efficiently test multiple drug combinations at once, rather than running separate trials for each. Patients who have never been treated will receive combinations of zimberelimab, domvanalimab, sacituzumab govitecan, and etrumadenant. Those who have already had treatment will receive different combinations, including GS-3583. There is no placebo group—every participant gets an active drug. If any of these combinations prove safe and effective, they could become new treatment options for lung cancer patients in the UK and beyond. The study is open-label, so both patients and doctors will know which drugs are being given. Around 25 sites across multiple countries, including the UK, will recruit participants.
View original technical description
This is a clinical research study aimed at individuals that have been diagnosed with a type of cancer called metastatic non-small cell lung cancer (NSCLC) and may have or may have not received prior treatment for this disease. The purpose of this study is to is to see if different combinations of experimental drugs are safe and effective when compared to approved treatments for NSCLC. The study will be divided into 2 different sub-studies depending on whether a participant has received previous disease treatment or not. For participants that have not received previous disease treatment, the study will test different combinations of zimberelimab, domvanalimab, sacituzumab govitecan and etrumadenant, whereas for participants that have received previous disease treatment the study will test different combinations of zimberelimab, sacituzumab govitecan, etrumadenant and GS-3583. Regardless of whether participants have received previous treatment or not, participants entering this study will receive study medication as there is no placebo (a substance known to be inactive). Sacituzumab govitecan is currently approved in the United Kingdom for the treatment of certain types of breast cancer and certain types of urothelial cancer, Zimberelimab is currently approved in China by the for the treatment of classical Hodgkin lymphoma whereas etrumadenant and domvanalimab have not yet been approved for the treatment of any disease.This research study will be conducted in a multicentre setting across different countries, where about 25 study sites will participate, including in the United Kingdom. This is an open-label study, meaning that the participant and the study doctor will know what study drugs the participant will be taking.This research is of vital importance as Lung cancer is the leading cause of cancer-related mortality worldwide. It was estimated that in 2020 there were over 2 million new cases of lung cancer and approximately 1.8 million deaths worldwide.
Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.
Is something wrong? Let us know